Kazia Therapeutics P/E
Cos'è P/E di Kazia Therapeutics?
P/E di Kazia Therapeutics Limited è N/A
Qual è la definizione di P/E?
Il rapporto prezzo / utili è il rapporto tra il prezzo delle azioni di una società e l'utile per azione della società calcolato su dodici mesi.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E di aziende nel Health Care settore su ASX rispetto a Kazia Therapeutics
Cosa fa Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Aziende con p/e simili a Kazia Therapeutics
- Big Ridge Gold ha P/E di N/A
- Babcock & Wilcox Enterprises Inc ha P/E di N/A
- Eurosport Active World ha P/E di N/A
- LOOPShare ha P/E di N/A
- Zenith Birla (India) ha P/E di N/A
- Codrus Minerals ha P/E di N/A
- Kazia Therapeutics ha P/E di N/A
- STI India ha P/E di N/A
- MIE ha P/E di N/A
- Granite Creek Copper ha P/E di N/A
- Beforepay Ltd ha P/E di N/A
- Vertu Capital ha P/E di N/A
- Nuchev ha P/E di N/A